Keywords: New Zealand, PHARMAC, Drug funding, Multople sclerosis, Bayer, Xarelto, Blood thinning, Antibiotics

New Zealand to offer wider access to MS treatments; new drugs in Bayer agreement

Article | 02 December 2010

Print This

New Zealand government drug funder PHARMAC will provide wider access to treatments for multiple sclerosis (MS), and fund new blood-thinning ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in